Acta Neuropathol

1. GOVAERTS CW, van Dijk JMC, van der Hoorn A, Kruyt FAE, et al
   Future directions in the treatment of brain metastases: evaluating the role of cellular players in the tumour microenvironment.
   Acta Neuropathol. 2026;151:58.
   

   >> Share

   
   

   
   BMC Cancer

2. QI F, Chen Y, Han Y, Jiang P, et al
   EGFR-TKI monotherapy versus combination therapy as first-line treatment for EGFR-mutant NSCLC with brain metastases: a real-world comparison analysis.
   BMC Cancer. 2026 May 20. doi: 10.1186/s12885-026-16193.
   

   >> Share

   
   
3. LIU D, Liu Y, Ci Y, Wang C, et al
   Efficacy and safety of targeted therapies for glioblastoma: a systematic review and network meta-analysis.
   BMC Cancer. 2026 May 18. doi: 10.1186/s12885-026-16190.
   

   >> Share

   
   

   
   BMC Neurol

4. KO K, Park YJ, Hwang K, Park YH, et al
   Reversibility of cognitive and psychiatric impairments following surgical resection of frontotemporal meningiomas: a predictive factor analysis.
   BMC Neurol. 2026 May 20. doi: 10.1186/s12883-026-04972.
   

   >> Share

   
   
5. DA R, Wang M, Jiang H, Wang W, et al
   BRAF-amplified glioblastoma patients have a worse prognosis than those with BRAF mutation and are associated with amplification of MET, RHEB and CUL1.
   BMC Neurol. 2026 May 18. doi: 10.1186/s12883-026-04982.
   

   >> Share

   
   

   
   Br J Cancer

6. SKRIBEK M, Livanou ME, Vathiotis I, Strandman V, et al
   The brain-lung immunotherapy prognostic (BLIP) Score: a novel robust tool for prognostication in non-small cell lung cancer patients with brain metastases.
   Br J Cancer. 2026 May 20. doi: 10.1038/s41416-026-03470.
   

   >> Share

   
   
7. WANG X, Xie Y, Hu J, Liu N, et al
   Furmonertinib combined with bevacizumab in EGFR-TKI-resistant leptomeningeal metastasis: analysis of the CSF ctDNA molecular response and survival outcomes.
   Br J Cancer. 2026;134:1614-1623.
   

   >> Share

   
   

   
   Cancer

8. KESSEL AC, Kim H, Brown PD, Lehrer EJ, et al
   Cost-effectiveness of vorasidenib in treatment of isocitrate dehydrogenase-mutated low-grade glioma.
   Cancer. 2026;132:e70463.
   

   >> Share

   
   

   
   Cancer Res

9. CLUBB JD, Shih RM, Gao TA, Shafer A, et al
   Armored chimeric antigen receptor T-cell therapy targets antigen-heterogeneous glioma.
   Cancer Res. 2026 May 20. doi: 10.1158/0008-5472.CAN-26-1515.
   

   >> Share

   
   

   
   Childs Nerv Syst

10. EROL A, Karagoz C, Ay LA, Cinar C, et al
    Delayed presentation of a pediatric giant traumatic pseudoaneurysm mimicking a brain tumor: a case report.
    Childs Nerv Syst. 2026;42:225.
    

    >> Share

    
    
11. VISOCCHI E, Camelia M, Spezzani C, Noris A, et al
    Primary intraosseous meningioma in a child: an unusual case report and literature review.
    Childs Nerv Syst. 2026;42:223.
    

    >> Share

    
    

    
    Clin Cancer Res

12. EHRET F, Horick NK, Yeap BY, Curry WT, et al
    Dose Escalation With Intensity-Modulated Proton Therapy for Patients with High-Risk Meningiomas - Results From a Phase 1 Trial.
    Clin Cancer Res. 2026 May 18. doi: 10.1158/1078-0432.CCR-25-3856.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

13. PERLOW HK, Hennings S, Bradshaw J, Reddy S, et al
    Preoperative Versus Postoperative Fractionated Stereotactic Radiation Therapy: A Single-Institution Analysis of 534 Resected Metastases.
    Int J Radiat Oncol Biol Phys. 2026;125:502-510.
    

    >> Share

    
    

    
    J Neurochem

14. GUERRIERO C, De Nuccio C, Petrone M, Rinaldi T, et al
    Dualsteric Agonist for M2 Muscarinic Receptor Causes Oxidative Stress and Mitochondrial Alteration in Human Glioblastoma Cancer Stem Cells.
    J Neurochem. 2026;170:e70454.
    

    >> Share

    
    

    
    J Neurooncol

15. WONG DKK, Pu JKS, Li LF, Hui VKH, et al
    Health-related quality-of-life of WHO grade 4 astrocytoma patients receiving alternating electrical field therapy: a prospective real-world multi-centre study.
    J Neurooncol. 2026;178:16.
    

    >> Share

    
    
16. PALIT SR, Shinya Y, Celda MP, Karsy M, et al
    Risk factors for postoperative cerebrospinal fluid leak following endoscopic transsphenoidal surgery for craniopharyngioma: a multicenter cohort study with a contemporary surgeon practice survey.
    J Neurooncol. 2026;178:13.
    

    >> Share

    
    
17. SKARIN N, Hallbeck M, Werlenius K, Rohan Z, et al
    MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencing.
    J Neurooncol. 2026;178:12.
    

    >> Share

    
    
18. JIA JL, Alshamsan B, Andronic C, Fazzari F, et al
    Treatment patterns and outcomes in high-risk WHO grade 2 diffuse glioma: a multicentre retrospective cohort study.
    J Neurooncol. 2026;178:10.
    

    >> Share

    
    
19. ZEYEN T, Decker A, Krause I, Kroh F, et al
    APTw CEST MRI in therapy-naive IDH-wildtype glioblastoma: insights into tumor heterogeneity and molecular subtypes.
    J Neurooncol. 2026;178:9.
    

    >> Share

    
    
20. VENTURA E, Alanesi A, Achterling M, Fistouris P, et al
    Impact of postoperative tumor volume and relative volume reduction to predict meningioma recurrence - a retrospective analysis.
    J Neurooncol. 2026;178:7.
    

    >> Share

    
    
21. SHIDOH-KAZUKI R, Fujikawa Y, Kawabata S, Tsujino K, et al
    Boron neutron capture therapy prolongs survival in a rat model of multifocal brain metastases.
    J Neurooncol. 2026;178:8.
    

    >> Share

    
    
22. BINDAL K, Dono A, Tandon N, Esquenazi Y, et al
    Laser interstitial thermal therapy versus stereotactic radiosurgery for first-time treatment of recurrent glioblastoma: a retrospective single-center study.
    J Neurooncol. 2026;178:6.
    

    >> Share

    
    
23. WIERZBICKI M, Bowden SG, Robert SM, Wang SY, et al
    Care pathways for asymptomatic brain metastases: comparison of healthcare utilization, costs, and outcomes in outpatient versus acute settings.
    J Neurooncol. 2026;178:5.
    

    >> Share

    
    
24. IZHAR M, Hori YS, Kattaa AH, Harary PM, et al
    Outcome of CyberKnife stereotactic radiosurgery for the brain metastases in patients with Li Fraumeni syndrome.
    J Neurooncol. 2026;178:4.
    

    >> Share

    
    
25. LEVIN-CARRION Y, Bhasin J, Titkov K, Anne S, et al
    Should checkpoint inhibitors be reserved for biomarker-selected pediatric brain tumors?
    J Neurooncol. 2026;178:2.
    

    >> Share

    
    
26. PALUMBO C, De Schlichting E, Le Lann F, Leboucher A, et al
    Timing of adjuvant chemoradiotherapy after resection and survival in glioblastoma: a single-centre cohort analysis.
    J Neurooncol. 2026;177:150.
    

    >> Share

    
    
27. BECHT K, Lindsay ME, Soulos PR, Singh C, et al
    Disparities in stereotactic radiosurgery receipt in patients with brain metastases from non-small cell lung cancer.
    J Neurooncol. 2026;177:151.
    

    >> Share

    
    
28. ARJUNA S, Pirhoushiaran M, Bueno A, Sanchez-Espitia A, et al
    CSF ctDNA analysis guides molecular reclassification of diffuse glioma patients.
    J Neurooncol. 2026;178:14.
    

    >> Share

    
    

    
    J Neurosurg

29. O'LEARY S, Fu AY, Rogers VA, Perdikis B, et al
    Optimal timing of PD-1 inhibitor immunotherapy administration to stereotactic radiosurgery in malignant gliomas: a propensity score-matched multi-institutional cohort study.
    J Neurosurg. 2026 May 15:1-12. doi: 10.3171/2025.12.JNS252327.
    

    >> Share

    
    

    
    Neuro Oncol

30. SMITH AA, Onar-Thomas A, Lensing S, Dalton J, et al
    Phase 3 randomized trial of postirradiation chemotherapy in patients with newly diagnosed ependymoma: A report from the Children's Oncology Group.
    Neuro Oncol. 2026;28:1286-1297.
    

    >> Share

    
    
31. SCHAFF LR, Pentsova E, Malani R, Stone J, et al
    Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine for newly diagnosed primary CNS lymphoma.
    Neuro Oncol. 2026;28:1277-1285.
    

    >> Share

    
    
32. TOS SM, Shaaban A, Hamdan D, Mantziaris G, et al
    Single-fraction stereotactic radiosurgery for residual, recurrent, or metastatic intracranial solitary fibrous tumors: An IRRF study toward management guidance.
    Neuro Oncol. 2026;28:1251-1265.
    

    >> Share

    
    
33. GHASEMI DR, Obrecht-Sturm D, Wallgren KM, Schuhmann MU, et al
    A brief history of ependymoma.
    Neuro Oncol. 2026;28:1085-1100.
    

    >> Share

    
    
34. RAJAN A, Castro FR, de Godoy LL, Hanaoka M, et al
    Imaging biomarkers for detecting IDH mutations and monitoring response to novel targeted therapies: Current insights and future perspectives.
    Neuro Oncol. 2026;28:1101-1116.
    

    >> Share

    
    
35. YEFET LS, Landry AP, Rogers CL, Wang JZ, et al
    Modern Molecular Profiling Recontextualizes the NRG/RTOG 0539 Trial and Reveals Hidden High-Risk and Radiotherapy Resistant Meningiomas.
    Neuro Oncol. 2026 May 15:noag081. doi: 10.1093.
    

    >> Share

    
    
36. LIU S, Bai Z, Qiao Y, Ge Y, et al
    LDHA-mediated CREB1 Lactylation Promotes Breast Cancer Brain Metastasis by Transcriptionally Activating Cytoskeletal Remodeling.
    Neuro Oncol. 2026 May 21:noag114. doi: 10.1093.
    

    >> Share

    
    
37. BRAMAN BC, Cady MA, Merz-Herrala AA, Witztum A, et al
    Epidemiological and clinical data link depot medroxyprogesterone acetate to meningioma.
    Neuro Oncol. 2026 May 21:noag115. doi: 10.1093.
    

    >> Share

    
    
38. 
    Corrigendum to: Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas.
    Neuro Oncol. 2026;28:e18.
    

    >> Share

    
    
39. KOTCH C, Perreault S, Power P, Adams DJ, et al
    Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade Glioma.
    Neuro Oncol. 2026 May 19:noag111. doi: 10.1093.
    

    >> Share

    
    
40. BRAT DJ, Aldape K, French PJ, Louis DN, et al
    cIMPACT-NOW update 12: Refining Pathology-based Risk Stratification and Grading for IDH-mutant Gliomas.
    Neuro Oncol. 2026 May 18:noag108. doi: 10.1093.
    

    >> Share

    
    
41. HIRUNPATTARASILP C, Newton HB
    The emerging roles of cerebral pericytes in brain metastasis.
    Neuro Oncol. 2026 May 19:noag110. doi: 10.1093.
    

    >> Share

    
    

    
    Neuroradiology

42. HE S, Li Z, Li J, Lin R, et al
    Multimodal integration of radiomics, pathomics, and clinical data enhances grading of adult diffuse gliomas using machine learning.
    Neuroradiology. 2026 May 19. doi: 10.1007/s00234-026-04015.
    

    >> Share

    
    
43. PRASAD S, Saini J, Dubey NK, Tsai LW, et al
    Beyond gross total resection (GTR): Deep peritumoral radiomics for predicting overall survival (OS) and O6-methylguanine-DNA-methyltransferase promoter methylation (MGMTpm) status in glioblastoma multiforme.
    Neuroradiology. 2026 May 18. doi: 10.1007/s00234-026-04016.
    

    >> Share

    
    
44. DEMIREL E, Dilek O
    T2-FLAIR digital subtraction radiomics versus neuroradiologist visual assessment for differentiating IDH-mutant astrocytomas from other non-enhancing low-grade gliomas: An externally validated machine learning study.
    Neuroradiology. 2026 May 15. doi: 10.1007/s00234-026-04025.
    

    >> Share

    
    

    
    Neurosurgery

45. LOZOUET M, Maquet C, Horion J, Garrido E, et al
    Complications of Cerebral Venous Thrombosis After Cerebellopontine Angle Tumor Resection: A STROBE Retrospective Observational Cohort Study.
    Neurosurgery. 2025 Oct 7. doi: 10.1227/neu.0000000000003761.
    

    >> Share

    
    
46. EVANS LR, Zhao YC, Castle-Kirszbaum M, Kam J, et al
    Improving the Assessment of Visual Outcomes After Resection of Tuberculum Sellae Meningiomas.
    Neurosurgery. 2026 May 19. doi: 10.1227/neu.0000000000004094.
    

    >> Share

    
    
47. PICHARDO-ROJAS PS, Pichardo-Rojas D, Ochoa-Hernandez D, Marin-Castaneda LA, et al
    Prognostic Validation of the RANO-Resect Classification and Non-Contrast-Enhancing Tumor Resection: A Meta-Science Study in Glioblastoma Surgery.
    Neurosurgery. 2026 May 19. doi: 10.1227/neu.0000000000004085.
    

    >> Share

    
    

    
    PLoS One

48. DEMIRAG AD, Aksoy RA, Akman G, Kaya V, et al
    Comprehensive quantum chemical analysis, vibrational spectroscopy, molecular docking, ADMET, and in vitro validation studies of hydroxychloroquine-MRGPRX2 complex in IDH-wildtype glioblastoma.
    PLoS One. 2026;21:e0347956.
    

    >> Share

    
    
49. KIRUBAKARAN M, Mohan J
    A novel hybrid framework integrating GA-driven 3D ResUNetGAN for MRI brain tumor segmentation.
    PLoS One. 2026;21:e0349451.
    

    >> Share

    
    
50. BLOMBERG L, Raba L, Bengzon J, Osther K, et al
    Overexpression of key complement regulators in glioblastoma.
    PLoS One. 2026;21:e0349101.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share